[1] Castillo J J,Ghobrial I M,Treon S P.Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation[J].Leuk Lymphoma,2016,57(11):2699-2701.
[2] 易树华,邱录贵.淋巴浆细胞淋巴瘤/华氏巨球蛋白血症发病机制研究进展[J].中华血液学杂志,2014,35(6):568-570.
[3] Treon S P,Xu L,Yang G,et al.MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia[J].N Engl J Med,2012,367(9):826-833.
[4] Jimenez C,Sebastian E,Chillon M C,et al.MYD88 L265P is a marker highly characteristic of,but not restricted to,Waldenstrom's macroglobulinemia[J].Leukemia,2013,27(8):1722-1728.
[5] Cao X,Medeiros L J,Xia Y,et al.Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression[J].Leuk Lymphoma,2016,57(5):1104-1113.
[6] King R L,Gonsalves W I,Ansell S M,et al.Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations[J].Am J Clin Pathol,2016,145(6):843-851.
[7] 邹德慧,易树华,刘慧敏,等.非IgM型淋巴浆细胞淋巴瘤临床及生物学特征研究[J].中华血液学杂志,2015,36(6):493-496.
[8] 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组,中国抗淋巴瘤联盟.淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(9):729-734.
[9] Treon S P,Tripsas C K,Meid K,et al.Ibrutinib in previously treated Waldenstrom's macroglobulinemia[J].N Engl J Med,2015,372(15):1430-1440.
[10] Chakraborty R,Kapoor P,Ansell S M, et al. Emerging therapeutic options for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma[J].Expert Rev Anticancer Ther,2015,15(10):1143-1156. |
